dc.creator | Carlos, G. | |
dc.creator | Uribe González, Pablo Francisco | |
dc.creator | Fernández-Peñas, P. | |
dc.date.accessioned | 2020-01-14T01:06:52Z | |
dc.date.available | 2020-01-14T01:06:52Z | |
dc.date.created | 2020-01-14T01:06:52Z | |
dc.date.issued | 2013 | |
dc.identifier | 0312-8008 | |
dc.identifier | https://repositorio.uc.cl/handle/11534/27447 | |
dc.identifier | 10.18773/austprescr.2013.063 | |
dc.description.abstract | Many dermatological conditions will respond to a topical corticosteroid. The clinical outcome will depend on making a correct clinical diagnosis and applying the right molecule in the most appropriate vehicle for the correct duration. Topical corticosteroids are classified by their strength, but the same molecule will have different effects depending on the vehicle. The patient's age and the affected area of skin are other important factors. If used correctly the adverse effects of topical corticosteroids are usually minimal. Systemic effects can occur with high doses. | |
dc.rights | acceso abierto | |
dc.subject | Atrophy | |
dc.subject | Cream | |
dc.subject | Ointment | |
dc.subject | Pregnancy | |
dc.subject | Vehicle | |
dc.subject | Betamethasone dipropionate | |
dc.subject | Betamethasone valerate | |
dc.subject | Clobetasol propionate | |
dc.subject | Clobetasone | |
dc.subject | Corticosteroid | |
dc.subject | Desonide | |
dc.subject | Drug vehicle | |
dc.subject | Emulsifying agent | |
dc.subject | Hydrocortisone | |
dc.subject | Hydrocortisone acetate | |
dc.subject | Methylprednisolone aceponate | |
dc.subject | Mometasone furoate | |
dc.subject | Triamcinolone acetonide | |
dc.subject | Acne | |
dc.subject | Adrenal cortex insufficiency | |
dc.subject | Age | |
dc.subject | Article | |
dc.subject | Clinical trial (topic) | |
dc.subject | Diabetes mellitus | |
dc.subject | Drug absorption | |
dc.subject | Drug classification | |
dc.subject | Drug efficacy | |
dc.subject | Drug indication | |
dc.subject | Drug penetration | |
dc.subject | Drug potency | |
dc.subject | Drug safety | |
dc.subject | Drug use | |
dc.subject | Drug withdrawal | |
dc.subject | Glaucoma | |
dc.subject | Human | |
dc.subject | Hyperglycemia | |
dc.subject | Hypopigmentation | |
dc.subject | Hypothalamus hypophysis adrenal system | |
dc.subject | Lactation | |
dc.subject | Lotion | |
dc.subject | Patient compliance | |
dc.subject | Perioral dermatitis | |
dc.subject | Prescription | |
dc.subject | Rash | |
dc.subject | Rosacea | |
dc.subject | Side effect | |
dc.subject | Skin atrophy | |
dc.subject | Skin disease | |
dc.subject | Tachyphylaxis | |
dc.subject | Treatment duration | |
dc.subject | Treatment response | |
dc.subject | Unspecified side effect | |
dc.subject | Vasoconstriction | |
dc.subject | Wound healing impairment | |
dc.title | Rational use of topical corticosteroids | |
dc.type | Artículo | |